Nivolumab-induced plaque morphea in a malign melanoma patient
Articles > Article ยท 2020
Authors: Ayda ACAR, Gokturk Oraloglu, Banu YAMAN, Isil Karaarslan
JOURNAL OF COSMETIC DERMATOLOGY, Journal Indexed in SCI Expanded, International, 2020, vol 20, pp 2645-2647
DOI: 10.1111/jocd.13914
Summary
Background Nivolumab is one of the targeted cancer therapy agent that acts to increase the immune responses by inhibition of antiprogrammed-death-receptor 1, which is one of the check points of the immune response. Nivolumab can be used to treat malign melanoma, lung, renal, head and neck, colorectal, hepatocellular cancers, and special cases of Hodgkin lymphoma.